Medication vs Medication
Wegovy Injection vs Wegovy Tablets
A practical UK comparison focused on what is genuinely different — not which brand has the loudest marketing.
The tablet is not simply an injection converted milligram-for-milligram. It has its own dosing schedule and OASIS 4 evidence.
Wegovy injection
STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed
Wegovy tablets
OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy
Side-by-side
| Wegovy injection | Wegovy tablets | |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| Form | Weekly injection | Daily tablet |
| Frequency | Once weekly | Once daily |
| Licence | UK weight management licence | UK weight management licence |
| NHS context | NICE-recommended in specialist weight-management pathways; access depends on pathway | Licensed; NICE/NHS positioning may lag the new formulation and should be checked live |
| Evidence | Very strong | Strong but newer formulation |
| Weight-loss evidence | STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed | OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy |
| Maintenance | Long-term support/treatment matters; weight regain after stopping has been demonstrated | Long-term treatment / maintenance planning still applies |
| GI considerations | Common GI effects; dose escalation is used to improve tolerability | GI effects remain common despite oral administration |
Reasons to discuss Wegovy injection
- Large evidence base
- Weekly dosing
- Cardiovascular outcome evidence in appropriate populations
- 2.4 mg established; 7.2 mg injectable option now licensed for adults with obesity if needed
Trade-offs
- Injection
- GI effects
- The new 7.2 mg option should not be compared using old 2.4 mg-only trial assumptions
- NHS access remains pathway-limited
Reasons to discuss Wegovy tablets
- Needle-free GLP-1 option
- Weight-management and maintenance licence
- Strong phase 3b efficacy
- Useful option for people strongly avoiding injections
Trade-offs
- Daily dosing
- Administration instructions and adherence matter
- Newer UK formulation with less real-world maturity
- NICE/NHS reimbursement position may differ from injectable Wegovy
Which is stronger for weight loss?
Wegovy injection is rated 8/10 and Wegovy tablets 8/10 in our comparison framework. That rating summarises the obesity evidence available for the licensed formulation; it is not a prediction of your result.
Which is easier to live with?
Wegovy injection: Once weekly. Wegovy tablets: Once daily. For some people a weekly injection is easier than a daily tablet; for others avoiding a needle is decisive.
NHS vs private reality
NICE-recommended in specialist weight-management pathways; access depends on pathway. Licensed; NICE/NHS positioning may lag the new formulation and should be checked live. NICE criteria and NHS availability are related but not identical, so check the current pathway rather than assuming a clinically eligible medicine is immediately available through a GP.
Maintenance matters
Long-term support/treatment matters; weight regain after stopping has been demonstrated. Long-term treatment / maintenance planning still applies. A treatment comparison that ends at the point of weight loss is incomplete.
Questions to ask a prescriber
- Which option is actually licensed and clinically appropriate for my health history?
- How do the expected benefits compare for someone with my diabetes/cardiovascular history?
- What side effects should make me contact you?
- What will monitoring involve?
- What is the plan if I cannot tolerate the maintenance dose?
- What happens if I stop?